Three biotechs set terms in a hunt for $475M-plus; Leap Ther­a­peu­tics earns a tri­al win across DKK1 high ex­press­ing tu­mors

We have a slate of biotech IPO terms to re­port this morn­ing.

De­sign Ther­a­peu­tics is ap­ply­ing a high val­u­a­tion to the com­pa­ny. The pre­clin­i­cal biotech wants to sell 12 mil­lion shares at $18 to $20 a pop, rais­ing more than $200 mil­lion with a hoped-for de­but val­u­a­tion of $1.1 bil­lion.

The gene­TAC com­pa­ny chose {DS­GN} for its tick­er.

The pre­clin­i­cal on­col­o­gy biotech Ike­na {IK­NA} says it will be sell­ing 7.8 mil­lion shares at $15 to $17 each for around $125 mil­lion. If suc­cess­ful, the com­pa­ny could de­but with a mar­ket cap worth more than $600 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER